structurebas
silico
virtual
drug
discoveri
procedur
assess
sever
acut
respiratori
syndrom
coronaviru
main
proteas
serv
case
studi
first
potenti
compound
extract
proteinligand
complex
select
protein
data
bank
databas
base
structur
similar
target
protein
later
set
compound
rank
dock
score
use
electron
highthroughput
screen
flexibl
dock
procedur
select
promis
molecul
set
best
perform
compound
use
similar
search
million
entri
ligandinfo
metadatabas
select
molecul
close
structur
relationship
may
provid
candid
lead
compound
toward
develop
novel
alloster
sever
acut
respiratori
syndrom
proteas
inhibitor
sever
acut
respiratori
syndrom
coronaviru
sarscov
recent
found
potent
pathogen
human
capabl
rapid
global
spread
lifethreaten
form
pneumonia
character
high
fever
nonproduct
cough
chill
myalgia
lymphopenia
progress
infiltr
indic
chest
radiographi
rel
emerg
year
ago
epidem
rapidli
spread
facilit
intern
air
travel
origin
guangdong
provinc
china
mani
countri
world
health
organ
report
sar
case
nearli
death
result
infect
sarsassoci
coronaviru
sarscov
sinc
variou
sarscov
protein
target
drug
discoveri
identifi
includ
sar
proteas
polymeras
helicas
studi
describ
silico
method
captur
key
featur
potenti
inhibitor
molecul
provid
specif
address
opportun
chemic
biolog
drug
design
approach
base
experiment
inform
contain
publicli
avail
databas
therefor
present
foundat
experiment
valid
genom
research
provid
ever
increas
number
potenti
drug
target
structur
biolog
allow
intens
use
avail
experiment
verifi
structur
data
variou
comput
project
studi
exploit
structur
homolog
sarscov
proteas
cocrystal
small
molecul
explor
opportun
drug
design
potenti
inhibitor
therapeut
target
enzym
crystal
structur
member
structur
classif
protein
scop
protein
famili
viral
cystein
proteas
trypsinfold
extract
protein
data
bank
pdb
databas
famili
part
trypsinlik
serin
proteas
superfamili
possess
close
barreltyp
structur
consist
two
domain
greekkey
duplic
scop
famili
viral
cystein
proteas
encompass
three
differ
group
structur
first
group
cystein
proteas
picornain
exemplifi
three
protein
human
rhinoviru
type
human
hepat
viru
polioviru
type
second
group
cystein
proteinas
singularli
exemplifi
protein
human
rhinoviru
third
group
coronaviru
main
proteinas
put
coronaviru
exemplifi
four
protein
transmiss
gastroenter
viru
transmiss
gastroenter
viru
human
coronaviru
sar
coronaviru
addit
sequenc
similar
search
perform
protein
pdb
databas
order
find
homolog
protein
structur
includ
recent
version
scop
databas
list
ligand
cocrystal
cystein
proteas
present
signific
chemic
divers
includ
peptid
small
molecul
inorgan
salt
ligand
structur
summar
tabl
includ
resolut
well
inform
locat
bind
insid
outsid
common
activ
site
ligand
structur
two
peptid
one
small
molecul
ie
chloroaceton
report
crystal
structur
sar
coronaviru
proteas
tabl
summar
known
ligand
cocryst
scop
famili
viral
cystein
proteas
trypsinfold
deposit
pdb
databas
approach
consid
molecul
relev
candid
lead
compound
lead
fragment
chemic
modif
eg
peptid
bond
replac
nonhydrolyz
bioisoster
also
note
initi
lead
compound
repres
comprehens
list
limit
relev
structur
deposit
pdb
databas
furthermor
molecul
report
respect
sar
drug
discoveri
includ
investig
swiss
pdbviewer
softwar
use
align
analyz
structur
threedimension
space
first
divid
avail
protein
chain
singl
domain
domain
structur
align
order
analyz
bind
mode
ligand
activ
site
align
structur
extract
protein
activ
site
ligand
locat
within
drug
design
strategi
use
templat
flexibl
dock
experi
order
adjust
conform
ligand
new
structur
context
target
structur
structur
align
ligand
cocrystal
structur
homolog
protein
subject
analysi
order
address
inconsist
pdb
databas
entri
certain
ligand
instanc
ligand
cocrystal
protein
structur
deposit
pdb
databas
lack
defin
atom
function
group
may
deform
represent
case
sarscov
mpro
enzym
ligand
molecul
chloroaceton
repres
chlorin
atom
henc
oxygen
carbon
atom
need
ad
obtain
complet
molecul
structur
pentapeptid
inhibitor
contain
crystal
structur
howev
cterminu
carboxyl
acid
deform
degre
carbon
atom
sp
instead
sp
hybrid
moreov
distanc
two
oxygen
atom
termin
carboxyl
moieti
chain
g
h
respect
origin
studi
provid
inform
one
expect
typic
carboxyl
moieti
cterminu
inhibitori
pentapeptid
henc
analysi
requir
prior
manual
remodel
reconstitut
desir
molecul
explor
use
structur
inform
contain
pdb
databas
silico
virtual
drug
discoveri
campaign
use
case
studi
main
proteas
sarscov
similar
approach
use
hiv
proteas
case
studi
report
ref
two
silico
method
employ
evalu
gather
structur
inform
pdb
databas
first
method
electron
highthroughput
screen
ehit
exhaust
flexibl
dock
method
systemat
cover
plewczynski
et
al
silico
predict
sar
inhibitor
plewczynski
et
al
silico
predict
sar
inhibitor
plewczynski
et
al
silico
predict
sar
inhibitor
signific
part
conform
posit
search
space
produc
highli
accur
dock
pose
speed
practic
virtual
highthroughput
screen
second
method
ligandinfo
system
design
fast
sensit
virtual
highthroughput
screen
smallmolecul
databas
ligandinfo
search
algorithm
base
twodimension
structur
similar
develop
system
enabl
search
similar
compound
larg
ligandinfo
metadatabas
contain
variou
publicli
avail
set
small
molecul
includ
harvard
chembank
encompass
bioactiv
compound
fdaapprov
drug
ii
chempdb
ligand
mark
hetero
atom
pdb
file
iii
kegg
ligand
molecul
found
kegg
pathway
iv
open
nation
cancer
institut
databas
total
size
metadatabas
exceed
million
entri
use
method
plausibl
inhibitor
gener
base
set
ligand
crystal
complex
protein
figur
two
dimension
chemic
structur
present
tabl
ii
plewczynski
et
al
target
protein
structur
homolog
famili
dock
perform
small
molecul
short
peptid
extract
proteinligand
complex
viral
cystein
proteas
trypsinfold
small
molecul
peptid
modifi
order
correct
chemic
attribut
ligand
structur
set
inhibitor
next
evalu
ehit
flexibl
dock
algorithm
toprank
ligand
summar
tabl
see
figur
chemic
structur
best
score
compound
first
set
origin
ligand
ehit
dock
score
two
analog
ehit
dock
score
respect
fourth
fifth
best
score
compound
origin
peptid
sar
target
pdb
code
chain
h
g
reflect
improv
initi
structur
ehit
dock
score
respect
case
crystal
structur
short
peptid
chain
g
h
interact
enzym
seen
crystal
structur
peptid
present
two
differ
conform
use
stare
point
ehit
result
determin
differ
cf
peptid
type
chain
h
type
chain
g
tabl
effect
observ
simpl
flexibl
molecul
mpd
exist
crystal
structur
variou
conform
use
start
point
ehit
calcul
yield
differ
result
thu
ehit
result
depend
choic
ligand
initi
conform
sever
reason
includ
part
molecul
recogn
ehit
rigid
block
may
rigid
treat
rigid
ii
flexibl
part
may
flexibl
enough
iii
search
may
adequ
comprehens
tend
think
depend
result
initi
conform
stem
combin
iii
ring
within
molecul
virtual
ident
variou
pose
produc
program
unfortun
suggest
could
confirm
could
identifi
inform
rel
part
molecul
treat
ehit
rigid
block
molecul
shown
tabl
use
screen
ligandinfo
metadatabas
queri
unfortun
almost
design
potenti
lead
compound
close
analog
metadatabas
subset
experiment
confirm
obvious
requir
chemic
synthesi
biolog
test
howev
mpd
alloster
inhibitor
except
similar
analog
mtc
found
use
mpd
queri
conclus
seri
lead
compound
potenti
sar
proteas
inhibitor
preliminarili
identifi
use
structurebas
silico
virtual
drug
discoveri
approach
howev
stress
mpd
analog
yet
report
date
rel
sar
proteas
inhibitor
drug
discoveri
also
importantli
mpd
chemic
addit
use
crystal
biolog
macromolecul
determin
costructur
vari
protein
limit
scop
famili
viral
cystein
proteas
trypsinfold
rel
sar
proteas
mpd
may
provid
candid
lead
compound
fragment
drug
discoveri
sever
select
mpd
analog
identifi
studi
test
experiment
sepsda
sinoeuropean
commiss
project
respect
potenti
sar
proteas
inhibitori
properti
